New flu vaccine tolerability survey completed with over 1,000 participants
NCT ID NCT06765187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how adults aged 18 and older experienced a trivalent recombinant influenza vaccine. Over 1,000 participants completed a short online survey about their injection experience, side effects, and willingness to get vaccinated again. The goal was to better understand vaccine tolerability and factors influencing vaccine choice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational site
Swiftwater, Pennsylvania, 18370, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- MRNA tech takes on the flu: could new shots outsmart seasonal strains?
- One shot for two viruses? new combo vaccine trial shows promise
- One shot for two viruses? combo COVID-Flu vaccine moves forward
- New mRNA vaccine targets bird flu pandemic threat
- New study monitors flu vaccine safety for seniors in korea
- German flu shot survey aims to boost vaccination rates